Ashvattha will present Phase 2 data on migaldendranib, a subcutaneous therapy for DME and wet AMD, which could offer a more patient-friendly alternative to current injection-based treatments Company ...

Receiving the SMC recommendation of LYTENAVA™ (bevacizumab gamma) for patients with wet AMD is a significant milestone for our company and a testament to our commitment to improving patient outcomes,” ...

GLP-1 drugs like Ozempic are associated with a higher risk of developing wet age-related macular degeneration in people with ...

Can AI really replace scientists? Robin, an AI system, identified a potential drug for vision loss, but scientists are ...

Metallic nanoparticles injected into the retina partly restored vision in blind mice and could work as a treatment for ...

Boyer discusses a potential treatment for diabetic retinopathy and macular degeneration using suprachoroidal injections, ...

Jay Chhablani, MD, explains how 3D choroidal vessel segmentation transforms ophthalmology, enhancing disease diagnosis and ...

Instead of receiving uncomfortable eye injections around once a month for a disease that can lead to blindness, patients may ...

Semaglutide drugs now include rare vision risk warning as studies link long-term use to optic neuropathy, macular ...

Newmedica has invested £3m in the opening of a new centre based in Welwyn Garden City, which it says aims to support local ...